S
| HTA ID | Drug | Brand | Indication | Assessment status | Date | |
| 25030 | Sulthaime | Ospolot® | Sulthiame (Ospolot®) oral suspension is indicated for the treatment of Self-Limited Epilepsy with Centrotemporal Spikes (SeLECTS) (former Rolandic epilepsy) in children and adolescents aged three years and above who are non-respondent/intolerant to other treatments or without other therapeutic alternatives. | Rapid Review Complete | 27th May 2025 |  |
| - | Sunitinib | Sutent® | As second-line treatment of patients with gastro-intestinal stromal tumours (GIST); As second line treatment for patients with metastatic renal cell carcinoma (mRCC) | Assessment process complete | 9th November 2006 | |